-
Oct 30, 2024 | 
onclive.com | Marc Braunstein
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine, discusses risk factors for veno-occlusive disease (VOD), management strategies, and prevention strategies in the post–hematopoietic stem cell transplant (HSCT) setting for patients with hematologic malignancies.
-
Sep 24, 2024 | 
kevinmd.com | Alisa Sano |Emily Watters |Marc Braunstein |Sarah Alnaher
Suppose you are looking for multivitamin supplements. You pick up two containers of multivitamins and wonder which one you should get. At first glance, they have similar labels, but then you notice that one has a comment indicating that the supplement was manufactured in a registered GMP-compliant facility, and the other does not. Then you ask yourself the following questions: How much of what ingredients are included in proprietary blends? Where do the ingredients come from?
-
Aug 24, 2024 | 
kevinmd.com | Marc Braunstein |Curtis Gattis |Leslie Gregory |Jillian Dawson
A patient recently came to my office seeking antibiotics for her viral URI symptoms. After a shared decision-making discussion on using Echinacea (an immunostimulant with antiviral, anti-inflammatory, and antimicrobial effects) instead, we were able to forgo the unnecessary antibiotic. Approximately 25 percent of U.S. adults report concurrently taking a dietary supplement with a prescription medicine.
-
Jul 5, 2024 | 
kevinmd.com | Sean Jordan |Peter Ubel |Marc Braunstein |Jaimie Cavanaugh
It is no secret that we are making great strides in reducing the mortality of lung cancer. From improving screening rates which have reduced the chances of dying from lung cancer due to earlier detection, increased adoption of minimally invasive surgical techniques, and exciting new drugs that have been shown to improve survival even in metastatic disease, there is reason to be hopeful in what has usually been a devastating and fatal diagnosis.
-
Jun 2, 2024 | 
kevinmd.com | Damane Zehra |Marc Braunstein |Jaimie Cavanaugh |Daryl James
If anyone asks me, “What part of oncology do you hate the most?” I would definitely answer without much thought, “geriatric oncology.” I think that’s the most difficult specialty because it needs extraordinary skills and patience to deal with elderly patients dealing with cancer. Although cancer is much more prevalent in the elderly, their needs are quite different compared to other adult patients.
-
May 3, 2024 | 
kevinmd.com | Marc Braunstein |Daniel Arteaga |Isobel Rosenthal |Irene Mathieu |Irène P. Mathieu
Today is the day I live for as a hematology/oncology fellowship program director. There are balloons filled on stage, dinner buffet stations brewing in the back of the conference room, and fellows entering with their proud families in tow for the graduation ceremony. On average, our graduating fellows have completed 14 years of education and training since high school and are finally about to enter the workforce as full-fledged oncologists.
-
Apr 23, 2024 | 
onclive.com | Marc Braunstein
Marc J. Braunstein, MD, PhD, FACP, associate professor of internal medicine, codirector of the Hematology Organ System, fellowship program director of Hematology-Oncology, NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers. Braunstein's research interests are in 3 general areas: hematologic malignancies, specifically lymphomas and plasma cell disorders; quality improvement; and medical education.
-
Apr 1, 2024 | 
kevinmd.com | Arthur Lazarus |Lisa DeFerrari |Marc Braunstein |Emily Hagen
In the realm of medicine, cause-and-effect relationships are those where a specific cause, such as a disease, condition, or treatment, directly leads to a specific outcome or effect. An example of this is the established fact that smoking causes lung cancer. Similarly, it is well-documented that regular, heavy alcohol consumption directly leads to liver cirrhosis.
-
Nov 29, 2023 | 
onclive.com | Marc Braunstein
November 29, 2023Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma. Marc J.
-
Nov 15, 2023 | 
kevinmd.com | John Pagel |Marc Braunstein |Michael Joyce |Don S. Dizon
This article is sponsored by Loxo@Lilly, the oncology unit of Eli Lilly and Company. In this special sponsored episode from Loxo@Lilly, I’m joined by Dr. John Pagel, senior vice president of clinical development and global head of hematology at Loxo@Lilly, to discuss blood cancer — what it is, advancements in research and treatment, and his experience in the field. There are an estimated 1.5 million people in the U.S. living with leukemia and lymphoma, which are types of blood cancer.
